Processa Pharmaceuticals Ownership 2024 | Who Owns Processa Pharmaceuticals Now?
Institutional Ownership
4.19%
Insider Ownership
10.68%
Retail Ownership
85.13%
Institutional Holders
18.00
Processa Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WELLS FARGO & COMPANY/MN | - | - | - | -3,247 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -28,139 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -42,786 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -234,653 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -46,306 | -100.00% | - | Mar 31, 2024 |
COURIER CAPITAL LLC | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -58,200 | -100.00% | - | Mar 31, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -18,677 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -122,033 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -293 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -315,410 | -100.00% | - | Mar 31, 2024 |
HRT FINANCIAL LP | - | - | - | -11,717 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,195 | -100.00% | - | Mar 31, 2024 |
ALLWORTH FINANCIAL LP | - | - | - | -1,700 | -100.00% | - | Mar 31, 2024 |
UBS GROUP AG | - | - | - | -80,023 | -100.00% | - | Mar 31, 2024 |
COASTAL BRIDGE ADVISORS, LLC | - | - | - | -64,956 | -100.00% | - | Mar 31, 2024 |
MCCOLLUM CHRISTOFERSON GROUP LLC | - | - | - | -12,500 | -100.00% | - | Mar 31, 2024 |
Processa Pharmaceuticals's largest institutional shareholder is WELLS FARGO & COMPANY/MN, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
WELLS FARGO & COMPANY/MN | - | - | - | -3,247 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -28,139 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -42,786 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -234,653 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -46,306 | -100.00% | - | Mar 31, 2024 |
COURIER CAPITAL LLC | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -58,200 | -100.00% | - | Mar 31, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -18,677 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -122,033 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -293 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -315,410 | -100.00% | - | Mar 31, 2024 |
HRT FINANCIAL LP | - | - | - | -11,717 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,195 | -100.00% | - | Mar 31, 2024 |
ALLWORTH FINANCIAL LP | - | - | - | -1,700 | -100.00% | - | Mar 31, 2024 |
UBS GROUP AG | - | - | - | -80,023 | -100.00% | - | Mar 31, 2024 |
COASTAL BRIDGE ADVISORS, LLC | - | - | - | -64,956 | -100.00% | - | Mar 31, 2024 |
MCCOLLUM CHRISTOFERSON GROUP LLC | - | - | - | -12,500 | -100.00% | - | Mar 31, 2024 |
The largest Processa Pharmaceuticals shareholder by % of total assets is WELLS FARGO & COMPANY/MN. The company owns 0.00 shares of Processa Pharmaceuticals (PCSA), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BLACKROCK INC. | - | - | - | -293 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,195 | -100.00% | - | Mar 31, 2024 |
ALLWORTH FINANCIAL LP | - | - | - | -1,700 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -3,247 | -100.00% | - | Mar 31, 2024 |
HRT FINANCIAL LP | - | - | - | -11,717 | -100.00% | - | Mar 31, 2024 |
COURIER CAPITAL LLC | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
MCCOLLUM CHRISTOFERSON GROUP LLC | - | - | - | -12,500 | -100.00% | - | Mar 31, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -18,677 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -28,139 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -42,786 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -46,306 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -58,200 | -100.00% | - | Mar 31, 2024 |
COASTAL BRIDGE ADVISORS, LLC | - | - | - | -64,956 | -100.00% | - | Mar 31, 2024 |
UBS GROUP AG | - | - | - | -80,023 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -122,033 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -234,653 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -315,410 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Processa Pharmaceuticals's largest institutional buyer is BLACKROCK INC.. The company purchased -0.29K stocks of PCSA, valued at -.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
CITADEL ADVISORS LLC | - | - | - | -315,410 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -234,653 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -122,033 | -100.00% | - | Mar 31, 2024 |
UBS GROUP AG | - | - | - | -80,023 | -100.00% | - | Mar 31, 2024 |
COASTAL BRIDGE ADVISORS, LLC | - | - | - | -64,956 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -58,200 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -46,306 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -42,786 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -28,139 | -100.00% | - | Mar 31, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -18,677 | -100.00% | - | Mar 31, 2024 |
MCCOLLUM CHRISTOFERSON GROUP LLC | - | - | - | -12,500 | -100.00% | - | Mar 31, 2024 |
COURIER CAPITAL LLC | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
HRT FINANCIAL LP | - | - | - | -11,717 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -3,247 | -100.00% | - | Mar 31, 2024 |
ALLWORTH FINANCIAL LP | - | - | - | -1,700 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,195 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -293 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Processa Pharmaceuticals's biggest institutional seller is CITADEL ADVISORS LLC. The company sold -0.32M shares of PCSA, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
CITADEL ADVISORS LLC | - | - | - | -315,410 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -234,653 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -122,033 | -100.00% | - | Mar 31, 2024 |
UBS GROUP AG | - | - | - | -80,023 | -100.00% | - | Mar 31, 2024 |
COASTAL BRIDGE ADVISORS, LLC | - | - | - | -64,956 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -58,200 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -46,306 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -42,786 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -28,139 | -100.00% | - | Mar 31, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -18,677 | -100.00% | - | Mar 31, 2024 |
MCCOLLUM CHRISTOFERSON GROUP LLC | - | - | - | -12,500 | -100.00% | - | Mar 31, 2024 |
COURIER CAPITAL LLC | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
HRT FINANCIAL LP | - | - | - | -11,717 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -3,247 | -100.00% | - | Mar 31, 2024 |
ALLWORTH FINANCIAL LP | - | - | - | -1,700 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -1,195 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -293 | -100.00% | - | Mar 31, 2024 |
Processa Pharmaceuticals's largest sold out institutional shareholder by shares sold is CITADEL ADVISORS LLC, sold -0.32M shares, valued at -, as of undefined.
Processa Pharmaceuticals Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
VANGUARD INDEX FUNDS | 0.00% | 469,306 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 118,169 | - | - | Feb 29, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 13,028 | - | - | Mar 31, 2024 |
Dimensional ETF Trust | 0.00% | 5,764 | - | - | Jan 31, 2024 |
DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 6,502 | - | - | Jan 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 2,103 | - | - | Mar 31, 2024 |
iSHARES TRUST | 0.00% | 27,006 | - | - | Mar 31, 2024 |
Processa Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 469.31K shares, compromising 0.00% of its total assets.
Processa Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Dec, 23 | 18 | -10.00% |
30 Sep, 23 | 20 | 11.11% |
30 Jun, 23 | 18 | -18.18% |
31 Mar, 23 | 22 | 22.22% |
31 Dec, 22 | 18 | - |
30 Sep, 22 | 18 | - |
30 Jun, 22 | 18 | 12.50% |
31 Mar, 22 | 16 | -5.88% |
31 Dec, 21 | 17 | -5.56% |
30 Sep, 21 | 18 | 12.50% |
30 Jun, 21 | 16 | 14.29% |
31 Mar, 21 | 14 | 75.00% |
31 Dec, 20 | 8 | - |
As of 31 Dec 23, 18 institutions are holding Processa Pharmaceuticals's shares, representing a decrease of -10.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Dec, 23 | 1,130,700 | -18.42% |
30 Sep, 23 | 1,386,038 | -0.25% |
30 Jun, 23 | 1,389,520 | -15.80% |
31 Mar, 23 | 1,650,245 | 42.14% |
31 Dec, 22 | 1,160,988 | 1.51% |
30 Sep, 22 | 1,143,740 | 0.97% |
30 Jun, 22 | 1,132,701 | 5.79% |
31 Mar, 22 | 1,070,679 | -18.91% |
31 Dec, 21 | 1,320,364 | -7.42% |
30 Sep, 21 | 1,426,159 | 4.10% |
30 Jun, 21 | 1,369,926 | 20.06% |
31 Mar, 21 | 1,141,050 | 48.50% |
31 Dec, 20 | 768,405 | - |
Processa Pharmaceuticals (PCSA) has 1.13M shares outstanding as of 31 Dec 23, down -18.42% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Dec, 23 | 4.19% | 15.81% |
30 Sep, 23 | 5.15% | 13.82% |
30 Jun, 23 | 6.10% | 11.62% |
31 Mar, 23 | 7.25% | 12.62% |
31 Dec, 22 | 7.58% | 15.20% |
30 Sep, 22 | 7.06% | 13.98% |
30 Jun, 22 | 7.11% | 15.54% |
31 Mar, 22 | 6.76% | 9.36% |
31 Dec, 21 | 8.50% | 10.08% |
30 Sep, 21 | 9.18% | 11.61% |
30 Jun, 21 | 8.89% | 14.53% |
31 Mar, 21 | 7.82% | 7.45% |
31 Dec, 20 | 10.25% | - |
As of 31 Dec 23, Processa Pharmaceuticals is held by 4.19% institutional shareholders, representing a 15.81% growth compared to 30 Sep 23.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Dec, 23 | 10 | -9.09% |
30 Sep, 23 | 11 | 120.00% |
30 Jun, 23 | 5 | -58.33% |
31 Mar, 23 | 12 | 33.33% |
31 Dec, 22 | 9 | 50.00% |
30 Sep, 22 | 6 | -14.29% |
30 Jun, 22 | 7 | 133.33% |
31 Mar, 22 | 3 | -25.00% |
31 Dec, 21 | 4 | -55.56% |
30 Sep, 21 | 9 | 28.57% |
30 Jun, 21 | 7 | -22.22% |
31 Mar, 21 | 9 | 12.50% |
31 Dec, 20 | 8 | - |
10 institutional shareholders have increased their position in PCSA stock as of 31 Dec 23 compared to 11 in the previous quarter (a -9.09% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Dec, 23 | 5 | 25.00% |
30 Sep, 23 | 4 | -42.86% |
30 Jun, 23 | 7 | 133.33% |
31 Mar, 23 | 3 | 200.00% |
31 Dec, 22 | 1 | - |
30 Sep, 22 | 1 | -50.00% |
30 Jun, 22 | 2 | -33.33% |
31 Mar, 22 | 3 | -50.00% |
31 Dec, 21 | 6 | 200.00% |
30 Sep, 21 | 2 | -50.00% |
30 Jun, 21 | 4 | -20.00% |
31 Mar, 21 | 5 | - |
31 Dec, 20 | - | - |
5 institutional shareholders have reduced their position in PCSA stock as of 31 Dec 23 compared to 4 in the previous quarter (a 25.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Dec, 23 | 18 | -10.00% | 1,130,700 | -18.42% | 4.19% | 15.81% | 10 | -9.09% | 5 | 25.00% |
30 Sep, 23 | 20 | 11.11% | 1,386,038 | -0.25% | 5.15% | 13.82% | 11 | 120.00% | 4 | -42.86% |
30 Jun, 23 | 18 | -18.18% | 1,389,520 | -15.80% | 6.10% | 11.62% | 5 | -58.33% | 7 | 133.33% |
31 Mar, 23 | 22 | 22.22% | 1,650,245 | 42.14% | 7.25% | 12.62% | 12 | 33.33% | 3 | 200.00% |
31 Dec, 22 | 18 | - | 1,160,988 | 1.51% | 7.58% | 15.20% | 9 | 50.00% | 1 | - |
30 Sep, 22 | 18 | - | 1,143,740 | 0.97% | 7.06% | 13.98% | 6 | -14.29% | 1 | -50.00% |
30 Jun, 22 | 18 | 12.50% | 1,132,701 | 5.79% | 7.11% | 15.54% | 7 | 133.33% | 2 | -33.33% |
31 Mar, 22 | 16 | -5.88% | 1,070,679 | -18.91% | 6.76% | 9.36% | 3 | -25.00% | 3 | -50.00% |
31 Dec, 21 | 17 | -5.56% | 1,320,364 | -7.42% | 8.50% | 10.08% | 4 | -55.56% | 6 | 200.00% |
30 Sep, 21 | 18 | 12.50% | 1,426,159 | 4.10% | 9.18% | 11.61% | 9 | 28.57% | 2 | -50.00% |
30 Jun, 21 | 16 | 14.29% | 1,369,926 | 20.06% | 8.89% | 14.53% | 7 | -22.22% | 4 | -20.00% |
31 Mar, 21 | 14 | 75.00% | 1,141,050 | 48.50% | 7.82% | 7.45% | 9 | 12.50% | 5 | - |
31 Dec, 20 | 8 | - | 768,405 | - | 10.25% | - | 8 | - | - | - |
Processa Pharmaceuticals Insider Shareholders Trades
Open Market Insider Trades
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of Processa Pharmaceuticals's stock was made by Bigora Sian on Aug 02 2024, selling 225 shares at $1.71 per share (valued at $384.75).
Processa Pharmaceuticals Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | 1 | - | - |
Q1 2024 | 11 | 10 | 110.00% |
Q4 2023 | 13 | 1 | 1300.00% |
Q3 2023 | 2 | - | - |
Q2 2023 | 15 | 5 | 300.00% |
Q1 2023 | 17 | 2 | 850.00% |
Q4 2022 | 9 | 2 | 450.00% |
Q3 2022 | 16 | 8 | 200.00% |
Q2 2022 | 13 | 2 | 650.00% |
Q1 2022 | 16 | 3 | 533.33% |
Q4 2021 | 16 | 8 | 200.00% |
Q3 2021 | 34 | 7 | 485.71% |
Q2 2021 | 10 | 8 | 125.00% |
Q1 2021 | - | 6 | - |
Q4 2020 | 5 | 20 | 25.00% |
Q2 2018 | - | 2 | - |
Q1 2005 | - | 2 | - |
Q3 2004 | - | 4 | - |
Q2 2004 | 1 | 1 | 100.00% |
1 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Processa Pharmaceuticals's insiders, as of Q3 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | - | - |
Q1 2024 | 6 | - | - |
Q4 2023 | - | - | - |
Q3 2023 | - | - | - |
Q2 2023 | 5 | - | - |
Q1 2023 | - | - | - |
Q4 2022 | - | - | - |
Q3 2022 | - | - | - |
Q2 2022 | 3 | - | - |
Q1 2022 | - | 1 | - |
Q4 2021 | 3 | 2 | 150.00% |
Q3 2021 | 1 | - | - |
Q2 2021 | 4 | 8 | 50.00% |
Q1 2021 | - | 6 | - |
Q4 2020 | 5 | - | - |
Q2 2018 | - | - | - |
Q1 2005 | - | - | - |
Q3 2004 | - | - | - |
Q2 2004 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Processa Pharmaceuticals's stocks.
Processa Pharmaceuticals Peer Ownership
Ticker | Company |
---|---|
PMVP | PMV Pharmaceuticals, Inc. |
FRTX | Fresh Tracks Therapeutics, Inc. |
IKT | Inhibikase Therapeutics, Inc. |
SABS | SAB Biotherapeutics, Inc. |
ACXP | Acurx Pharmaceuticals, Inc. |
INBX | Inhibrx, Inc. |
FENC | Fennec Pharmaceuticals Inc. |
SCPS | Scopus BioPharma Inc. |
AKTX | Akari Therapeutics, Plc |
ANTX | AN2 Therapeutics, Inc. |
THRD | Third Harmonic Bio, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
CELC | Celcuity Inc. |
MACK | Merrimack Pharmaceuticals, Inc. |
ELVN | Enliven Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |
PCSA Ownership FAQ
Who Owns Processa Pharmaceuticals?
Processa Pharmaceuticals is owned by institutional shareholders (4.19%), insiders (10.68%), and public (85.13%). The largest institutional shareholder of Processa Pharmaceuticals is WELLS FARGO & COMPANY/MN (0% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).
Who are the major institutional shareholders of Processa Pharmaceuticals?
Processa Pharmaceuticals's major institutional shareholders are WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, STATE STREET CORP, VANGUARD GROUP INC, and ROYAL BANK OF CANADA. The top five shareholders own together 0% of the company's share outstanding.
How many Processa Pharmaceuticals shareholders are there?
As of Dec 2023, there are 18 institutional shareholders of Processa Pharmaceuticals.
What percentage of Processa Pharmaceuticals is owned by WELLS FARGO & COMPANY/MN?
WELLS FARGO & COMPANY/MN owns 0 shares of Processa Pharmaceuticals, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).
What percentage of Processa Pharmaceuticals is owned by NORTHERN TRUST CORP?
As of Mar 2024, NORTHERN TRUST CORP holds 0 shares of Processa Pharmaceuticals (PCSA), compromising 0% of the company, valued at $0.
What percentage of Processa Pharmaceuticals is owned by STATE STREET CORP?
STATE STREET CORP is the third largest holder of Processa Pharmaceuticals. The company owns 0 of the company's shares outstanding (worth $0).